Bennett DE, Courval JM, Onorato I, Agerton T, Gibson JD, Lambert L, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999–2000. Am J Respir Crit Care Med. 2008;177:348–55.
Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh Jr CR. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol. 2014;179:216–25.
Centers for Disease Control and Prevention. CDC Report 2011. National diabetes fact sheet. Atlanta, GA: Centers for Disease Control and Prevention. [http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf]
Leung CC, Lam TH, Chan WM, Yew WW, Ho KS, Leung GM, et al. Diabetic control and risk of tuberculosis: a cohort study. Am J Epidemiol. 2008;167:1486–94.
Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health. 1997;87:574–9.
Restrepo BI, Camerlin AJ, Rahbar MH, Wang W, Restrepo MA, Zarate I, et al. Cross-sectional assessment reveals high diabetes prevalence among newly-diagnosed tuberculosis cases. Bull World Health Organ. 2011;89:352–9.
Dyck RF, Klomp H, Marciniuk DD, Tan L, Stang MR, Ward HA, et al. The relationship between diabetes and tuberculosis in Saskatchewan: comparison of registered Indians and other Saskatchewan people. Can J Public Health. 2007;98:55–9.
World Health Organization. WHO Report 2011. Collaborative framework for care and control of tuberculosis and diabetes. Geneva: World Health Organization. [http://whqlibdoc.who.int/publications/2011/9789241502252_eng.pdf]. Access Date: 1–5–2012.
Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9:737–46.
Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff TH, et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis. 2007;45:428–35.
Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis. 2006;43:848–54.
Baker MA, Lin HH, Chang HY, Murray MB. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clin Infect Dis. 2012;54:818–25.
Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5:e152.
Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lonnroth K, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81.
Corris V, Unwin N, Critchley J. Quantifying the association between tuberculosis and diabetes in the US: a case–control analysis. Chronic Illn. 2012;8:121–34.
US Census Bureau. American Community Survey 2010. [http://factfinder2.census.gov/faces/nav/jsf/pages/index.xhtml]. Access Date: 2–1–2012.
Tuberculosis Control Branch. Report on tuberculosis in California, 2012. Richmond, CA: California Department of Public Health; 2013.
Centers for Disease Control and Prevention. Trends in tuberculosis--United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62:201–5.
Moonan PK, Ghosh S, Oeltmann JE, Kammerer JS, Cowan LS, Navin TR. Using genotyping and geospatial scanning to estimate recent mycobacterium tuberculosis transmission, United States. Emerg Infect Dis. 2012;18:458–65.
Ricks PM, Cain KP, Oeltmann JE, Kammerer JS, Moonan PK. Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the U.S., 2005–2009. PLoS One. 2011;6:e27405.
Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med. 2006;173:927–31.
Hill AN, Becerra J, Castro KG. Modelling tuberculosis trends in the USA. Epidemiol Infect. 2012;140:1862–72.
Centers for Disease Control and Prevention. Report of verified case of tuberculosis (RVCT) instruction manual. Atlanta, GA: Centers for Disease Control and Prevention. 2009. [www.cdc.gov/tb/programs/rvct/InstructionManual.pdf]
Office of Management and Budget. Revisions to the standards for the classification of federal data on race and ethnicity. 10–30–1997. Washington, DC: Executive Office of the President. [www.whitehouse.gov/omb/fedreg_1997standards/]
California Health Interview Survey. CHIS 2011–2012 Adult Public Use File [computer file]. Los Angeles, CA: UCLA Center for Health Policy Research, July 2013.
Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ. 1998;317:307–12.
Rose DN. Benefits of screening for latent mycobacterium tuberculosis infection. Arch Intern Med. 2000;160:1513–21.
Linas BP, Wong AY, Freedberg KA, Horsburgh Jr CR. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med. 2011;184:590–601.
Walsh MC, Camerlin AJ, Miles R, Pino P, Martinez P, Mora-Guzman F, et al. The sensitivity of interferon-gamma release assays is not compromised in tuberculosis patients with diabetes. Int J Tuberc Lung Dis. 2011;15:179–iii.
Gotzsche PC, Jorgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;6, CD001877.
Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;1, CD004720.
Centers for Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011;60:1650–3.
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155–66.
Ponce-De-Leon A, Garcia-Garcia Md ML, Garcia-Sancho MC, Gomez-Perez FJ, Valdespino-Gomez JL, Olaiz-Fernandez G, et al. Tuberculosis and diabetes in southern Mexico. Diabetes Care. 2004;27:1584–90.
Dobler CC, Flack JR, Marks GB. Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study. BMJ Open. 2012;2:e000666.
World Health Organization. Tuberculosis country profiles. Geneva: World Health Organization; 2013. [http://www.who.int/tb/country/data/profiles/en/index.html]. Access date: 1–11–2013.
Narayan KM, Aviles-Santa L, Oza-Frank R, Pandey M, Curb JD, McNeely M, et al. Report of a National heart, lung, and blood Institute workshop: heterogeneity in cardiometabolic risk in Asian Americans in the U.S. opportunities for research. J Am Coll Cardiol. 2010;55:966–73.
Araneta MR, Barrett-Connor E. Ethnic differences in visceral adipose tissue and type 2 diabetes: Filipino, African-American, and white women. Obes Res. 2005;13:1458–65.
Araneta MR, Wingard DL, Barrett-Connor E. Type 2 diabetes and metabolic syndrome in Filipina-American women: a high-risk nonobese population. Diabetes Care. 2002;25:494–9.
Karter AJ, Schillinger D, Adams AS, Moffet HH, Liu J, Adler NE, et al. Elevated rates of diabetes in Pacific Islanders and Asian subgroups: the diabetes study of Northern California (DISTANCE). Diabetes Care. 2013;36:574–9.
Lonnroth K, Williams BG, Cegielski P, Dye C. A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol. 2010;39:149–55.